Law360, New York (February 21, 2006, 12:00 AM ET) -- Biotechnology company MedImmune Inc. gained another chance to fight off rival Genentech Inc. this week, with the U.S. Supreme Court agreeing to hear the previously dismissed case centering on whether a company must refuse to pay royalties before challenging a patent claim.
MedImmune has long been defending patent claims against Genentech for methods MedImmune uses to make Synagis, a drug designed to prevent dangerous respiratory tract infections in infants.
In 2003, MedImmune sued Genentech in the U.S. District Court for the Central District of California, seeking...
MedImmune-Genentech Battle Moves To High Court
To view the full article, take a free trial now.
